Infectious Disease Control

At Zymeron, our talented scientists discover and advance precision medicine technologies to prevent and treat infectious diseases and immunological disorders. Zymeron’s precision bioengineering capability enables the action and effect of pharmaceutical agents at specific biomolecular and subcellular targets.

Anti-Infective Therapeutics

Our anti-infective therapeutics (AIT) program focuses on discovering new drug targets and novel mechanisms of action and developing novel compounds and formulation strategies that can better mitigate the drug resistance problem. Drug resistance is a consequence of infectious agent evolution in part responding to biological pressures imposed on these microorganisms. Our AIT technologies take aim at reducing the likelihood of drug resistance development and minimizing the probability of microorganisms to genetically pass the drug resistance traits down during replication. Our AIT program focuses on 1) Targeted Protein Degradation; and 2) Preventive Therapeutics.

Targeted Protein Degradation

Targeted protein degradation is a disruptive drug technology that has the potential to enable game changing antiviral therapeutic capabilities. The principle of this novel strategy utilizes chimeric, tripartite molecules that bind to the target protein including those that are previously undruggable, triggering its polyubiquitination by ubiquitin-activating enzymes, uniquitin-conjugating enzymes, and ubiquitin ligases. The polyubiquitin protein tag marks the substrate protein for subsequent degradation in the proteasome. The chimera compounds, small molecule protein degraders, orchestrate the “kiss of death” for the target protein. Contrary to traditional small molecule inhibitors, protein degraders offer the advantage of completely abrogating all catalytic, structural and scaffolding functions of the protein. Protein degraders only need transient binding to induce ubiquitination and therefore require lower binding affinity and are less susceptible to point mutations. Our protein degraders target viral and host proteins that are crucial to virion entry and replication, or chronic infection. These protein degraders are developed as the next generation antivirals for viruses that either lack functional cure or have widespread drug resistance problems.

Long Acting Preventive Medicine

Zymeron develops preventive therapeutics to control the spreading of infectious agents at the point of mosquito-to-human transmission. We have an established long-lasting implant technology that is capable of sustaining the release of small molecule drugs from two weeks to at least twelve months. The implants have precisely engineered shell thickness, pore size and pore volume that modulate the release kinetics of the active molecules from the drug core. The subdermal implants are physiological depots loaded with preventive anti-infectives to offer sustained protection to individuals who go to areas where transmission occurs. The biggest advantages of long-releasing drug implants over oral or parenteral drugs include improved medication adherence and reduced logistic burdens for travelers and field workers. Our unique implant device has the following advantages and benefits.

  • Reservoir-based, slow release implants
  • Pre-programmed drug release rates (duration of release)
  • Constant release rates help reach pharmacokinetic steady states rapidly
  • Bioresorbable implant materials
  • Injected through syringe needles or inserted via an incision
  • Active drug loading greater than 90% permitting higher drug dose and longer duration of effect
  • Compatible with hydrophobic and hydrophilic drugs
  • Cylinder-shaped, matchstick-sized solid implants

Cumulative Drug Release

Daily Drug Release

Vaccine Portfolio

Zymeron forms a multidisciplinary vaccine business unit to strengthen our vaccine portfolio of technologies including guided immunogen and adjuvant delivery systems, immunological diagnostic tools, and recombinant immunogen production methods. Our vaccine program develops revolutionary immunogen-adjuvant codelivery technologies to bring next generation capability to prevent and control viral infections and to deliver a step-change in vaccine performance. Our vaccine product development efforts target autoimmune diseases and acquired immunodeficiency disorders.

  • Tolerogenic vaccine-adjuvant delivery systems
  • Nanoparticle-based adjuvants
  • Staged release immunogen-adjuvant delivery systems

Our vaccine team works closely with the POCT team to develop rapid diagnostic assays to validate and monitor immunological markers for: 1) accelerating the preclinical and clinical vaccine development; and 2) screening vaccination eligibility. The vaccine team also collaborates with the Advanced Materials team to develop abiotic affinity resins for recombinant protein purification as a cost-effective alternative to immunoaffinity chromatography.